Drug Trial Radar · NCT06801509
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine
Last checked: Nov 19, 2026Latest source record: Jan 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Feb 15, 2025
Primary completion
Nov 10, 2025
Study completion Oct 10, 2027
Sponsor
- Lead sponsor
- Sinocelltech Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purposes of the study are to evaluate the Safety, Tolerability, and Immunogenicity of different dose levels of recombinant herpes zoster vaccine with 2 doses 60 days apart in healthy subjects aged 40 years and older.
Conditions
- Herpes Zoster
Interventions
Recombinant Herpes Zoster Vaccine (SCTV04C) Low-DoseBiological
Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Immunization procedure: 2 doses, 60 days apart;
Recombinant Herpes Zoster Vaccine (SCTV04C) High-DoseBiological
Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Immunization procedure: 2 doses, 60 days apart;
Placebo control: SalineBiological
The placebo in this study is 0.9% sodium chloride (normal saline) injection; Immunization procedure: 2 doses, 60 days apart;
Shingrix®Biological
Route of vaccination: intramuscular injection into the lateral deltoid of the upper arm; Dosage of vaccination: 50 μg; Immunization procedure: 2 doses, 60 days apart
Ganwei®Biological
Route of vaccination: subcutaneous injection into the lateral deltoid of the upper arm; Dosage of vaccination: 0.5 mL; Immunization procedure: saline will be administered at Day 0, and Ganwei® will be administered at Day 60;
Primary outcomes
What the sponsor says the trial is designed to measure.
- phase 1: Incidence and intensity of solicited adverse events (AEs)Time frame: within 14 days after each vaccination
- phase 1: Incidence and intensity of unsolicited AEsTime frame: within 30 days after each vaccination
- phase 2: Geometric mean concentration (GMC) and seroconversion rate of antigen-specific antibodyTime frame: at 30 days after full vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dazhu CDC
Dazhou, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.